Microbix Biosystms (TSE:MBX) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Microbix Biosystems has teamed up with EMQN to launch a novel genetic-test program aimed at identifying patients susceptible to antibiotic-induced hearing loss. This initiative, which utilizes Microbix’s quality assessment products, is crucial for ensuring accurate diagnoses and effective treatment plans, particularly for newborns at risk of severe infections.
For further insights into TSE:MBX stock, check out TipRanks’ Stock Analysis page.